The Neuralink study will involve a brain-computer interface being implanted in a brain region that controls movement.
Those with paralysis due to cervical spinal cord injury or amyotrophic lateral sclerosis may qualify for the study, it said but did not reveal how many participants would be enrolled in the trial, which will take about six years to complete. The company, which had earlier hoped to receive approval to implant its device in 10 patients, was negotiating a lower number of patients with the US Food and Drug Administration after the agency raised safety concerns, according to current and former employees.Musk has grand ambitions for Neuralink, saying it would facilitate speedy surgical insertions of its chip devices to treat conditions like obesity, autism, depression, and schizophrenia.